These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 12001649)

  • 41. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease.
    Sriram K; Matheson JM; Benkovic SA; Miller DB; Luster MI; O'Callaghan JP
    FASEB J; 2002 Sep; 16(11):1474-6. PubMed ID: 12205053
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease].
    Matsubara K
    Nihon Hoigaku Zasshi; 1998 Oct; 52(5):301-5. PubMed ID: 10077975
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model.
    Maetzler W; Berg D; Schalamberidze N; Melms A; Schott K; Mueller JC; Liaw L; Gasser T; Nitsch C
    Neurobiol Dis; 2007 Mar; 25(3):473-82. PubMed ID: 17188882
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys.
    Vázquez-Claverie M; Garrido-Gil P; San Sebastián W; Izal-Azcárate A; Belzunegui S; Marcilla I; López B; Luquin MR
    J Neuropathol Exp Neurol; 2009 Sep; 68(9):977-84. PubMed ID: 19680145
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease.
    Depboylu C; Schorlemmer K; Klietz M; Oertel WH; Weihe E; Höglinger GU; Schäfer MK
    J Neuroimmunol; 2011 Jul; 236(1-2):39-46. PubMed ID: 21640391
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Striatal TH-immunopositive fibers recover after an intrastriatal injection of 6-hydroxydopamine in golden hamsters treated with prednisolone: roles of tumor necrosis factor-α and inducible nitric oxide synthase in neurodegeneration.
    Rodríguez S; Uchida K; Nakayama H
    Neurosci Res; 2013; 76(1-2):83-92. PubMed ID: 23471013
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.
    Recasens A; Dehay B; Bové J; Carballo-Carbajal I; Dovero S; Pérez-Villalba A; Fernagut PO; Blesa J; Parent A; Perier C; Fariñas I; Obeso JA; Bezard E; Vila M
    Ann Neurol; 2014 Mar; 75(3):351-62. PubMed ID: 24243558
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The role of alpha-synuclein in Parkinson's disease].
    Miklya I; Pencz N; Hafenscher F; Göltl P
    Neuropsychopharmacol Hung; 2014 Jun; 16(2):77-84. PubMed ID: 24978050
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inflammation and neurodegeneration: the story 'retolled'.
    Drouin-Ouellet J; Cicchetti F
    Trends Pharmacol Sci; 2012 Oct; 33(10):542-51. PubMed ID: 22944460
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [New clues to the etiology of Parkinson disease: parkinsonism induced by the neurotoxin MPTP].
    Jonsson G; Sundström E
    Lakartidningen; 1986 Jan; 83(4):215-8. PubMed ID: 3485230
    [No Abstract]   [Full Text] [Related]  

  • 52. Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys.
    Hurley SD; O'Banion MK; Song DD; Arana FS; Olschowka JA; Haber SN
    Exp Neurol; 2003 Dec; 184(2):659-68. PubMed ID: 14769357
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel anti-inflammatory therapy for Parkinson's disease.
    Gao HM; Liu B; Zhang W; Hong JS
    Trends Pharmacol Sci; 2003 Aug; 24(8):395-401. PubMed ID: 12915048
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CNI-1493 attenuates neuroinflammation and dopaminergic neurodegeneration in the acute MPTP mouse model of Parkinson's disease.
    Noelker C; Stuckenholz V; Reese JP; Alvarez-Fischer D; Sankowski R; Rausch T; Oertel WH; Hartmann A; van Patten S; Al-Abed Y; Bacher M
    Neurodegener Dis; 2013; 12(2):103-10. PubMed ID: 23147695
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Neurochemical methods].
    Agid Y
    Rev Electroencephalogr Neurophysiol Clin; 1976; 6(4):444-6. PubMed ID: 14358
    [No Abstract]   [Full Text] [Related]  

  • 56. Calcium hypothesis of neurodegeneration - An update.
    Bezprozvanny I
    Biochem Biophys Res Commun; 2019 Dec; 520(4):667-669. PubMed ID: 31761066
    [No Abstract]   [Full Text] [Related]  

  • 57. Role of inflammatory factors in neurodegeneration.
    Członkowska A; Kurkowska-Jastrzebska I; Członkowski A
    Neurol Neurochir Pol; 2001; 35 Suppl 3():13-22. PubMed ID: 12001649
    [No Abstract]   [Full Text] [Related]  

  • 58. [Treatment of neurodegenerative diseases: new perspectives].
    Członkowska A; Kurkowska-Jastrzebska I
    Neurol Neurochir Pol; 2001; 35(4 Suppl):147-56. PubMed ID: 11873614
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation.
    De Lella Ezcurra AL; Chertoff M; Ferrari C; Graciarena M; Pitossi F
    Neurobiol Dis; 2010 Mar; 37(3):630-40. PubMed ID: 19969084
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inflammation and neurodegeneration in Parkinson's disease.
    McGeer PL; McGeer EG
    Parkinsonism Relat Disord; 2004 May; 10 Suppl 1():S3-7. PubMed ID: 15109580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.